-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MIL-62 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MIL-62 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MIL-62 in Follicular Lymphoma Drug Details: MIL-62 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MIL-62 in Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MIL-62 in Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MIL-62 in Chronic Lymphocytic Leukemia (CLL) Drug Details: MIL-62 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MIL-62 in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MIL-62 in Marginal Zone B-cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MIL-62 in Marginal Zone B-cell Lymphoma Drug Details: MIL-62 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MIL-62 in Splenic Marginal Zone B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MIL-62 in Splenic Marginal Zone B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MIL-62 in Splenic Marginal Zone B-Cell Lymphoma Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MIL-62 in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MIL-62 in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MIL-62 in Extranodal Marginal...
-
Product Insights
Mil-e Nader Wind Farm
Mil-e Nader Wind Farm is an Onshore Wind project located in Sistan and Baluchistan, Iran. The project is owned and developed by Kasra Torbin Sistan. The project is currently under construction. Empower your strategies with our Mil-e Nader Wind Farm report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of...
-
Product Insights
Mil Nader_ Mapna Wind Farm
Mil Nader_ Mapna Wind Farm is an onshore wind project located in Sistan and Baluchistan, Iran. The project is owned and developed by MAPNA Renewable Energies Generation Co. The project is currently partially active. Empower your strategies with our Mil Nader_ Mapna Wind Farm report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MIL-62 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MIL-62 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MIL-62 in Follicular Lymphoma Drug Details: MIL-62 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MIL-62 in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MIL-62 in Marginal Zone B-cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MIL-62 in Marginal Zone B-cell Lymphoma Drug Details: MIL-62 is...
-
Sector Analysis
NewAcrylonitrile Industry Capacity and Capital Expenditure Forecasts with Details of All Active and Planned Plants to 2028
Acrylonitrile Industry Capacity & Capital Expenditure (Capex) Overview The acrylonitrile industry capacity was 9.55 million tonnes per annum (mtpa) in 2023. China, the US, South Korea, Japan, and Taiwan were the key countries accounting for most of the acrylonitrile capacity in 2023. The acrylonitrile industry capacity will garner an AAGR of more than 4% from 2023 to 2028. In terms of global Capex spending non acrylonitrile industry planned and announced projects, Asia will account for the largest regional share with...